New hope for rare disease: drug may ease skin stiffness in systemic sclerosis
NCT ID NCT05300932
First seen Jan 28, 2026 · Last updated May 24, 2026 · Updated 12 times
Summary
This study tests whether baricitinib, an oral drug, can reduce skin hardening in people with systemic sclerosis, a rare autoimmune disease. About 60 adults with early diffuse systemic sclerosis will receive either baricitinib or a placebo for 24 weeks. The main goal is to measure changes in skin thickness using a standard scoring system, while also tracking side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department of RheumatologyTongji Hospital
Wuhan, Hubei, 430030, China
-
Tongji Hospital
Wuhan, Hubei, 430030, China
Conditions
Explore the condition pages connected to this study.